Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. by Rosenzweig, E.B. et al.
Paediatric pulmonary arterial
hypertension: updates on definition,
classification, diagnostics and management
Erika B. Rosenzweig1, Steven H. Abman2, Ian Adatia3, Maurice Beghetti4,
Damien Bonnet5, Sheila Haworth6, D. Dunbar Ivy2 and Rolf M.F. Berger7
Number 12 in the series
“Proceedings of the 6th World Symposium on Pulmonary Hypertension”
Edited by N. Galiè, V.V. McLaughlin, L.J. Rubin and G. Simonneau
Affiliations: 1Columbia University Medical Center, New York Presbyterian Hospital, New York, NY, USA.
2University of Colorado, Children’s Hospital Colorado, Denver, CO, USA. 3Glenwood Children’s Heart Clinic,
Edmonton, AB, Canada. 4Pediatric Cardiology Unit and Centre Universitaire de Cardiologie et Chirurgie
Cardiaque Pédiatrique, University Hospitals of Geneva and Lausanne, Lausanne, Switzerland. 5Hôpital Necker
Enfants Malades, AP-HP, Université Paris Descartes, Paris, France. 6University College London, London, UK.
7Center for Congenital Heart Diseases, Pediatric Cardiology, Beatrix Children’s Hospital, University Medical
Center Groningen, University of Groningen, Groningen, The Netherlands.
Correspondence: Erika B. Rosenzweig, Pulmonary Hypertension Comprehensive Care Center, Columbia
University Medical Center, New York Presbyterian Hospital, 3959 Broadway, New York, NY 10032, USA.
E-mail: esb14@cumc.columbia.edu
@ERSpublications
State of the art and future perspectives in paediatric pulmonary hypertension with special emphasis
on classification, diagnosis and treatment http://ow.ly/uVPo30mksOj
Cite this article as: Rosenzweig EB, Abman SH, Adatia I, et al. Paediatric pulmonary arterial hypertension:
updates on definition, classification, diagnostics and management. Eur Respir J 2019; 53: 1801916 [https://
doi.org/10.1183/13993003.01916-2018].
ABSTRACT Paediatric pulmonary arterial hypertension (PAH) shares common features of adult disease,
but is associated with several additional disorders and challenges that require unique approaches. This
article discusses recent advances, ongoing challenges and distinct approaches for the care of children with
PAH, as presented by the Paediatric Task Force of the 6th World Symposium on Pulmonary
Hypertension. We provide updates of the current definition, epidemiology, classification, diagnostics and
treatment of paediatric PAH, and identify critical knowledge gaps. Several features of paediatric PAH
including the prominence of neonatal PAH, especially in pre-term infants with developmental lung
diseases, and novel genetic causes of paediatric PAH are highlighted. The use of cardiac catheterisation as
a diagnostic modality and haemodynamic definitions of PAH, including acute vasoreactivity, are
addressed. Updates are provided on issues related to utility of the previous classification system to reflect
paediatric-specific aetiologies and approaches to medical and interventional management of PAH,
including the Potts shunt. Although a lack of clinical trial data for the use of PAH-targeted therapy
persists, emerging data are improving the identification of appropriate targets for goal-oriented therapy in
children. Such data will likely improve future clinical trial design to enhance outcomes in paediatric PAH.
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Introduction
Pulmonary hypertension (PH) in children is associated with diverse diseases with onset at any age. The
distribution of aetiologies in paediatric PH is quite different to that of adults, with children having a
greater predominance of idiopathic pulmonary arterial hypertension (IPAH), pulmonary arterial
hypertension (PAH) associated with congenital heart disease (PAH-CHD) and developmental lung
diseases. Differences in aetiology, presentation and outcomes require a unique approach in children. The
management of children remains challenging because treatments have long depended on evidence-based
adult studies and the clinical experience of paediatric experts. Although there is still a lack of data on
effectiveness, formulation, pharmacokinetics, optimal dosing and treatment strategies, data are emerging
that allow for the definition of appropriate treatment targets and goal-oriented therapy in children.
Nevertheless, children with PAH are currently treated with targeted PAH drugs with benefit. We provide
an overview of recent updates in the current definition, epidemiology, classification, diagnostics and
treatment of PAH in children, and identify current needs based on discussions and recommendations
from the Paediatric Task Force of the 6th World Symposium on Pulmonary Hypertension (WSPH) in
Nice, France (2018).
Definitions
Historically, the definition of PH in children has been the same as in adults, i.e. mean pulmonary arterial
pressure (mPAP) ⩾25 mmHg. In the normal fetal circulation, PAP is similar to systemic pressure and
rapidly falls after birth, achieving levels that are similar to the adult by 2–3 months of age. Due to
variability in pulmonary haemodynamics during post-natal transition, paediatric PH has been defined as
mPAP ⩾25 mmHg after 3 months of age. In paediatric PH, especially in association with CHD, it is
recommended to use pulmonary vascular resistance (PVR) as indexed to body surface area (PVRI) in
order to assess the presence of pulmonary vascular disease (PVD), as defined by PVRI ⩾3 WU·m2.
The 6th WSPH proposed to modify the definition for PH in adults as mPAP >20 mmHg and to include
PVR ⩾3 WU to identify pre-capillary PH. Whether or not the same findings of high normal or “borderline
PH” with mPAP of 21–24 mmHg in subgroups of adult PH such as scleroderma, chronic obstructive
pulmonary disease and interstitial lung disease is a risk factor for developing PAH and related morbidities
in children as in adults will require further study [1]. However, in order to speak a universal language and
facilitate transition from paediatric to adult PH care, the Paediatric Task Force chose to follow the newly
proposed adult definition of PH and encourages further study of these patients. The proposed use of PVR
to assess PVD at the 6th WSPH had already been included previously in the haemodynamic assessment of
PH in children. The Paediatric Task Force further reinforced the need for indexing of PVR in children.
Vasoreactivity
In IPAH/heritable PAH (HPAH), acute vasodilator testing (AVT) is recommended to identify patients
who are likely to have a good long-term prognosis when treated with long-term calcium channel blocker
(CCB) therapy. In the recent past, positive vasoreactivity was believed to be more common in children
with IPAH when compared with adults and that specific response criteria were indicated for children.
However, using the same criteria for adult and paediatric subjects with IPAH/HPAH showed that the
proportion of AVT responders was similar in both age groups [2]. A recent large study including 382
patients showed a substantial discrepancy in how AVT is performed and interpreted in children, and that
standardisation is required [2]. As in adults, inhaled nitric oxide at 10–80 ppm is the preferred agent, but
i.v. epoprostenol, i.v. adenosine or inhaled iloprost may be used as alternatives. However, optimal dosing
in small children is not well defined for the latter drugs. As recently reported, the Sitbon criteria for
positive AVT, as defined by a decrease in mPAP by at least 10 mmHg to a value of <40 mmHg with
sustained cardiac output that is commonly used in adult IPAH/HPAH, have been shown to identify children
who will show sustained benefit from CCB therapy [2, 3]. Positive AVT in subjects with mPAP <40 mmHg
at baseline is defined by a drop of at least 10 mmHg without a fall in cardiac output. Based on these data it
is advised to use the Sitbon criteria for AVT in children. Since it has been shown that only half of the
adult responders have a long-term haemodynamic and clinical improvement on CCB therapy, close
long-term follow-up is required.
Can AVT predict operability if resting PAP and PVR are elevated in children with CHD and open
systemic-to-pulmonary shunts?
In CHD-associated PH, AVT is often performed for other reasons than determining the potential use of
CCB therapy and predictor of outcome, as shown in IPAH/HPAH. AVT is also used to distinguish
between reversible and progressive PAH in patients with PAH-CHD, and thus potential operability [4].
However, specific criteria for defining a positive AVT response or specific haemodynamic targets that
predict reversal of PAH and good long-term prognosis following surgical correction remain lacking.
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In fact, other factors beyond the haemodynamic response to AVT have been shown to be associated with
PAH reversal after surgical repair, including age, type of cardiac lesion, comorbidities, resting and exercise
saturation, and clinical history. In the absence of robust data on haemodynamic predictors, current
guidelines suggest criteria for operability of CHD in the presence of PAH that are based on expert
opinion. The Paediatric Task Force agreed on general guidance for assessing operability in CHD-PAH, but
emphasises that the long-term impact of defect closure in the presence of PAH with increased PVR is
unknown (table 1).
Updates in paediatric PH epidemiology and classification
Current epidemiological data on paediatric PH are mainly derived from registry cohorts; as a result they
are affected by study design, logistics and the scope of clinical practice underlying patient selection for
these registries. Geographic coverage, referral patterns, inclusion criteria and disease definitions may differ
between registries, leading to potential selection bias that can affect reported incidence and prevalence
rates. The estimated incidence of sustained PH in all categories was reported at 4–10 cases per million
children per year with a prevalence of 20–40 cases per million in Europe (Spain, the Netherlands) and 5–8
cases per million children per year and 26–33 per million children in the USA [5–7]. A Dutch nationwide
epidemiological study, that minimised potential bias by including all hospitals in the country by
combining hospital registries with local paediatric cardiology databases over a 15-year period, reported an
annual incident rate of PH in children of 63.7 per million children [6]. The majority of children (2845 out
of 3262) had “transient” PAH and were infants with either persistent PH of the newborn (PPHN) or
repairable cardiac shunt defects. Of the remaining children, 27% had other forms of PAH (IPAH,
PAH-CHD, PAH associated with connective tissue disease (CTD) and pulmonary veno-occlusive disease
(PVOD)), while a significant proportion (34%) had PH associated with developmental lung disease,
including bronchopulmonary dysplasia (BPD), congenital diaphragmatic hernia (CDH) and congenital
pulmonary vascular abnormalities [6].
Group 1: PAH
Group 1.1: IPAH
Estimated incidence rates for IPAH vary from 0.47 to 1–2 cases per million children, with estimated
prevalence rates from 2.1 to 4.4 cases per million children [5–9].
Group 1.2: HPAH
As in adult PAH, gene mutations that have been implicated in the pathogenesis of HPAH have been
identified in 20–30% of paediatric sporadic PAH cases and 70–80% of familial PAH cases. These include
known mutations such as those in BMPR2 (bone morphogenetic protein receptor type 2) and ACVRL1
(activin receptor-like kinase 1). However, compared with adult PAH, the genetic architecture of paediatric
PAH differs and seems enriched in TBX4 and ACVRL1 mutations [10–13]. Whether mutation carriers in
paediatric PAH have a different phenotype or clinical course than non-carriers remains to be
demonstrated [11]. Furthermore, paediatric PAH is frequently associated with chromosome and syndromic
anomalies, in which the mechanistic basis for PAH is generally uncertain. A recent exome sequencing
study in paediatric PAH suggests that de novo variants in novel genes may explain approximately 19% of
paediatric-onset IPAH cases. The prevalence of known PAH gene mutations in PAH-CHD is controversial
as several studies have not detected PAH mutations in these patients, whereas other groups have identified
BMPR2 mutations in patients presenting with PAH after correction of a defect [11, 14], and a recent study
shows variants in SOX17 associated with PAH-CHD [15]. Genetic testing is still not performed routinely
in all paediatric PH as it may lead to significant psychological impacts, particularly in asymptomatic
TABLE 1 Guidance for assessing operability in pulmonary arterial hypertension associated with
congenital heart disease
Pulmonary vascular resistance
index WU·m2
Pulmonary vascular
resistance WU
Correctability/favourable long-term
outcome
<4 <2.3 Yes
4–8 2.3–4.6 Individual patient evaluation in
tertiary centres
>8 >4.6 No
WU: Wood Units. Special considerations include: age of patient, type of defect, comorbidities, resting or
exercise-induced desaturation is a concern and PAH therapy (treat with intent-to-repair approach has not
been proven).
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individuals, especially in the setting of incomplete penetrance. Genetic testing should be combined with
genetic counselling by experts in this field so that families have all information before and after testing.
The genetics of PH and genetic testing specifically in paediatrics requires further work and should be
performed in expert centres with a genetic counselling group.
Group 1.3: Drug- and toxin-induced PAH
Several cases of transient PAH that resolved after discontinuation of diazoxide have been described in the
literature, suggesting that hyperinsulinaemic and hypoglycaemic neonates treated with diazoxide require
echocardiographic surveillance [16]. The US Food and Drug Administration (FDA) issued a warning
about diazoxide and PAH in neonates in 2015 [17].
Group 1.4: Associated PAH
Group 1.4.1: PAH associated with CTD
PAH-CTD in children is uncommon, but deterioration is usually rapid when associated with PAH.
PAH-CTD occurs in 0–4% of patients in PH clinics [5–7, 18–21]. In a multinational cohort of 389
children with systemic juvenile arthritis from the CARRA registry, 16 (4%) were diagnosed with PAH [18].
A recent study suggests that PAH was diagnosed by echocardiography in 2% of a cohort of 850 children
with systemic lupus erythematosus within the first 2 years of diagnosis, These patients with PH were
mostly asymptomatic and, in some cases, the PAH resolved or improved [19].
Group 1.4.2: PAH associated with HIV infection
PAH-HIV in children appears to be rare outside of endemic areas, with one case in each of the Spanish,
Dutch and UK registries [5, 6, 22].
Group 1.4.3: PAH associated with portal hypertension
Patients with liver disease suffer from two distinct pulmonary vascular complications: hepatopulmonary
syndrome (HPS) and portopulmonary hypertension (POPH). Whereas HPS is characterised by increased
pulmonary blood flow, low PVR and hypoxaemia, POPH has striking pulmonary vascular remodelling
that adversely affects the outcome of orthotopic liver transplantation [23]. POPH appears to be rare in
children, with 0–2% of cases reported in PH registries [5, 6, 22, 24].
Group 1.4.4: Congenital heart disease
Group 1.4.4 PAH includes patients with simple operable and inoperable CHD, subgrouped as those with
Eisenmenger physiology, those with PAH and left-to-right shunts, those with PAH thought to be
incidental to their CHD and those with postoperative/closed defects. This classification for PAH associated
with cardiac or arterial shunt has not changed since the previous WSPH 2013 classification [25]. Transient
PH following repair of congenital heart disease occurs in 21.9 cases per million and is one of the
commonest forms of PAH in children, second only to persistent pulmonary hypertension of the newborn
[6]. Complex heart diseases have been assigned to group 5.4.
Group 1.4.5: Schistosomiasis
Schistosomiasis is uncommon in developed countries and lacks studies of targeted PH therapy in children.
Group 1.5: PAH long-term responders to CCBs
As in adults, a subgroup of children with IPAH can be identified who are positive AVT responders and
would now be classified as “PAH long-term responders to CCBs” [25]. Based on the Sitbon criteria, this
subgroup is estimated to include roughly 8–15% of the children with IPAH.
Group 1.6: PAH with overt features of venous/capillaries (PVOD/PCH) involvement
PAH with overt features of venous/capillaries (PVOD/pulmonary capillary haemangiomatosis (PCH))
involvement in children appears to be rare. PVOD and/or PCH was diagnosed in 0.7–2% cases of PAH in
the Spanish, Dutch and TOPP registries [5, 6, 26]. The EIF2AK4 (eukaryotic translation initiation factor
2α kinase 4) mutation was present in two-thirds of children diagnosed with PVOD in France [11].
Group 1.7: Persistent PH of the newborn syndrome
PPHN is the most common cause of transient PAH (30.1 cases per million children per year) and may be
increasing in frequency [7]. In the era before inhaled nitric oxide therapy, PPHN occurred in
approximately 2 per 1000 live births [27]. In contrast, between 2003 and 2012, the prevalence of PPHN
among 12954 extremely pre-term infants enrolled was 8.1% (95% CI 7.7–8.6%), with the trend increasing
annually, in part due to increased survival of extremely low-birthweight infants and growing awareness of
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PPHN in pre-terms. The proportion of newborns with PPHN is inversely related to gestational age, with
an incidence of 18.5% (range 15.2–22.4%) for infants born at 22–24 weeks compared with 4.4% (range
3.8–5.2%) for those born at 27 weeks [28]. The current WSPH Paediatric Task Force emphasised that
PPHN is a syndrome with multiple associated conditions (table 2). Although multifactorial in origin,
recent epidemiological studies show that PPHN is associated with ante-natal events, including
pre-eclampsia, chorioamnionitis and other peri-natal events, leading to abnormal pulmonary vascular
growth and function, and perhaps increasing the risk for PAH later in life [26].
Group 2: PH due to left heart disease
Very little epidemiological data are available on this condition in children; however, left ventricular
diastolic dysfunction and impaired myocardial performance can contribute to PH severity in diverse
settings, including PPHN, BPD and CDH. Congenital left heart inflow/outflow obstructions are common
in children with CHD, and outcome is dependent on aetiology and the stage in pulmonary vascular
development that the obstruction occurs. Pulmonary vein stenosis, which has a very poor prognosis, can
complicate the course and is emerging as an important cause of sustained PH, especially in the setting of
ex-premature infants with BPD [29–32]. Table 3 shows congenital post-capillary obstructive lesions most
frequent in childhood now classified as group 2.4 PH
Group 3: PH due to lung diseases and/or hypoxia
Group 3.5: Developmental lung disorders
This category comprises an important and increasingly recognised proportion of children with PH. BPD is
a common developmental disorder of prematurity that is characterised by impaired alveolar and vascular
growth and maturation. Past registry data report that 10–12% of children with PH have associated lung
disease, with BPD being the most common disorder [26, 33]. This might likely be an underrepresentation
of its frequency due to bias in registry enrolment, as previously mentioned. The Netherlands
epidemiological study revealed that 34% of patients with sustained PH have developmental lung disease.
The incidence and prevalence of severe BPD and PH increase with increasing survival of 23–26-week
pre-terms. In a prospective study, PH at 7 days of age was present in 42% of premature babies (birthweight
500–1250 g) and was associated with late PH (at 36 weeks corrected age) in 14%, worse severity of BPD,
longer need for mechanical ventilation and neonatal intensive care unit hospitalisation, and higher
mortality [34, 35]. In children with BPD, PH can resolve with respiratory and PH-targeted drug therapy
over time; however, even in the surfactant era the morbidity and mortality of PH in BPD infants remains
high. Recent meta-analyses found that the presence of PH in premature born infants was strongly
associated with mortality (risk ratio 4.7) with an accumulative estimated mortality rate of 16% prior to
discharge and of 40% during the first 2 years of life. However, the same meta-analyses identified that most
reports have studied selected patient populations, and accurate estimates of incidence and prevalence rates
later in life are lacking [36]. No trials have yet been conducted to formally assess the effect of PH-specific
therapies on children with BPD.
TABLE 3 Congenital post-capillary obstructive lesions (group 2.4)
Pulmonary vein stenosis
Isolated
Associated (bronchopulmonary dysplasia, prematurity)
Cor triatriatum
Obstructed total anomalous pulmonary venous return
Mitral/aortic stenosis (including supra/subvalvular)
Coarctation of the aorta
TABLE 2 Persistent pulmonary hypertension of the newborn (PPHN) and associated disorders
Idiopathic PPHN Myocardial dysfunction (asphyxia, infection)
Down syndrome Structural cardiac diseases
Meconium aspiration syndrome Hepatic and cerebral arteriovenous malformations
Respiratory distress syndrome
Transient tachypnoea of the newborn Associations with other diseases:
Pneumonia/sepsis Placental dysfunction (pre-eclampsia, chorioamnionitis, maternal hypertension)
Developmental lung disease Metabolic disease
Peri-natal stress Maternal drug use or smoking
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Table 4 provides a summary of developmental lung disorders that share the common feature of
developmental vascular disturbances.
Group 4: PH due to pulmonary artery obstructions
Chronic thromboembolic PH remains uncommon as a cause of PAH in children, at around 0–1.4% of
cases [22, 26]. In contrast, pulmonary artery obstructions occur in a number of CHDs, either congenitally
or acquired after corrective surgery [25].
Group 5: PH with unclear and/or multifactorial mechanisms
Group 5.4: Complex CHD
This group includes haematological disorders, systemic and metabolic disorders, others, and complex
CHD. Of specific interest for the paediatric age group are complex heart diseases that are associated with
congenital anomalies of the pulmonary vasculature such as segmental disorders, single ventricle physiology
and the scimitar syndrome (table 5). PH in these settings is extremely difficult to define or classify [37].
After extensive discussion at the 5th WSPH in 2013, the Paediatric Task Force agreed to classify several
anomalies with differential pulmonary blood flow under the category of “segmental PH”, indicating the
distinct nature of these entities when compared with other forms of PH [38, 39].
During the current 6th WSPH, the Paediatric Task Force also considered including patients with single
ventricle physiology as representing yet another difficult group to define; this group continues to increase
and represents a significant proportion of subjects with PVD at major medical centres. At various stages
these patients may have increased or decreased pulmonary blood flow, and as they reach an age suitable
for the Fontan procedure or total cavo-pulmonary connection these subjects have variable degrees of PVD
and bronchopulmonary collaterals. Subsequently, the chronic non-pulsatile pulmonary circulation
associated with a Fontan circulation likely induces a very specific form of PVD that is dissimilar to PVD
in other diseases associated with PH [40]. Patients with Fontan circulation do not usually fulfil the
definition of PH with mPAP >20–25 mmHg and, accordingly, these patients were previously excluded
from the official WSPH classification. Nevertheless, these patients develop PVD that markedly impacts
survival and, according to the Paediatric Task Force, PVD in the setting of single ventricle physiology
deserves inclusion and has been classified with other forms of group 5 PH. The nature and mechanisms
underlying the pathobiology of PVD in this setting urgently require further investigation.
TABLE 4 Developmental lung disorders associated with pulmonary hypertension
Bronchopulmonary dysplasia
Congenital diaphragmatic hernia
Down syndrome
Alveolar capillary dysplasia with “misalignment of veins” (FOXF1)
Lung hypoplasia, acinar dysplasia
Surfactant protein abnormalities
Surfactant protein B deficiency
Surfactant protein C deficiency
ABCA3
TTF1/NKX2-1
TBX4
Pulmonary interstitial glycogenesis
Pulmonary alveolar proteinosis
Pulmonary lymphangiectasia
TABLE 5 Complex congenital heart disease (group 5.4)
Segmental pulmonary hypertension
Isolated pulmonary artery of ductal origin
Absent pulmonary artery
Pulmonary atresia with ventricular septal defect and major aorto-pulmonary collateral arteries
Hemitruncus
Other
Single ventricle
Unoperated
Operated
Scimitar syndrome
https://doi.org/10.1183/13993003.01916-2018 6
WORLD SYMPOSIUM ON PULMONARY HYPERTENSION | E.B. ROSENZWEIG ET AL.
In these complex CHD categories (group 5.4), the general definition of PH does not suffice and should be
customised. At present, there is insufficient data showing that targeted therapies are safe and efficient in this
population, and further studies are required [41, 42].
Additional special considerations for paediatric clinical classification
The WSPH classification for PH was originally designed for adults with PH. The rationale for a clinical
classification includes the ability to strengthen clinical practice, including enhanced diagnostic and
management strategies, and to help provide guidance for prioritising laboratory, translational and
epidemiological research questions. In addition, goals for improving classification systems include the need
for clarification of disease phenotype, encouraging new thinking on causation and disease pathobiology,
enhancement of diagnostic evaluations, improvements in correlations of phenotype and therapeutic
responsiveness, and enhancement of clinical trial design.
While the major categories of PH as classified by the WSPH have been shown to be helpful also in
neonates and children, there are persistent and important gaps that should be considered to improve their
utility in these specific age groups.
In 2013, the first WSPH Paediatric Task Force reasoned that a common classification for both adults and
children is preferred, since children with PH who were diagnosed in the neonatal through adolescent age
ranges are now surviving into adulthood and such classification will facilitate transition from paediatric to
adult services. They then proposed several modifications in order to highlight aspects of paediatric
disorders and better address specific features of paediatric PH within the core of the existing classification.
These modifications included the designation of PPHN as a subclass within group 1 disorders, more
detailed categorisation of PAH in CHD, the addition of congenital left heart inflow and outflow tract to
group 2, and the introduction of the category of “developmental lung disease” to group 3 and of
“segmental PH” to group 5.
In 2018, the WSPH Paediatric Task Force aimed to further capture specific paediatric features in the WSPH
clinical classification, while preserving the main core of the classification as given in table 2 of the Task Force
article by SIMONNEAU et al. [25] in this issue of the European Respiratory Journal. They proposed additional
further refinements of these groups as discussed in the previous subsections, including a separate designation
for congenital/acquired cardiovascular conditions leading to post-capillary PH (group 2.4), developmental
lung disorders (group 3.5), other pulmonary artery obstructions (group 4.2) and complex CHD (group 5.4)
Recent observational paediatric data reveal that PAH in “older” children, despite specific differences,
shares many common features with adult PAH. However, PH presenting in neonates is often associated
with developmental vascular abnormalities and responses, and in the current classification is assigned to
group 3 PH associated with lung disease and/or hypoxia. These PVDs are much less comparable to adult
PH, since the impact of PH on the immature, developing lung is recognised as a major factor integral to
the presentation, diagnosis, response to therapy and outcome, both immediate and long term. It is clear
that although paediatric and adult PH share common features, the aetiology, epidemiology and
presentation of neonatal and paediatric PVD differ significantly from those in adults. One of the
distinguishing features of PH in children is the injury of the developing fetal, neonatal and paediatric lung
circulation [43]. Another distinguishing feature is the frequent association with chromosome, genetic and
syndromic anomalies (11–52%), and the phenotypic associations that may result in multifactorial causes of
PH in up to 33% of cases [5, 44].
The current WSPH Paediatric Task Force therefore proposed to designate the developmental (vascular) lung
disorders as a special subcategory within group 3 PH (group 3.5). In addition to the recognised frequency
and importance of PVD and PH in disorders such as BPD and CDH, this category includes a rapidly
expanding list of newly recognised genetic developmental lung disorders, including surfactant abnormalities,
pulmonary interstitial glycogenesis, alveolar capillary dysplasia, TBX4 mutations and others (table 4).
Paediatric PVDs are often associated with multiple comorbidities that may contribute to PH severity and
dictate overall outcomes. As discussed, the genetic background of paediatric PH appears to differ from that
of adult PH, and accompanying genetic disorders, syndromes and growth abnormalities are frequent in
children with PH. Whether these latter should be regarded as causally related, disease modifiers or
innocent bystanders is often not clear. Therefore, accurate phenotyping of children with PH and
assessment of the effect on outcome of comorbidities remains of crucial importance in any classification.
Down syndrome
An illustrative example of the complex role of comorbidities in paediatric PH warranting further attention
is Down syndrome. This Paediatric Task Force discussed the unique clinical phenotype of neonates, infants
and children with Down syndrome, and the potential role for PH screening in this group.
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Down syndrome, or trisomy 21, is associated with significant cardiovascular and pulmonary morbidity
and mortality in children, including PH, chronic hypoxaemia and recurrent respiratory illnesses. Newborn
infants with Down syndrome are at high risk of developing severe PPHN at birth and often have more
aggressive PVD secondary to CHD or airways obstruction than do subjects without Down syndrome.
Mechanisms that increase the susceptibility of infants and children with Down syndrome to develop worse
PH and cardiorespiratory disease are incompletely understood. Past studies have shown that infants dying
with Down syndrome can have evidence of lung hypoplasia as demonstrated by decreased alveolarisation,
peripheral lung cysts and persistence of the double-capillary network [45]. These early abnormalities of
arrested lung development may contribute to increased susceptibility for more aggressive cardiovascular
and respiratory diseases in Down syndrome. Although mechanisms for abnormal lung and lung vascular
development are uncertain, recent work has shown that three antiangiogenic (anti-vascular endothelial
growth factor) genes are present on chromosome 21, and are each overexpressed in human fetal and infant
lung tissue, including endostatin, RCAN-1 (regulator of calcineurin-1) and β-amyloid peptide.
Experimentally, early disruption of angiogenic signalling decreases vascular growth and increases the risk
for PH, and also impairs distal airspace (alveolar) growth [46, 47]. Overall, these laboratory and clinical
findings suggest that subjects with Down syndrome are highly susceptible to decreased lung vascular and
alveolar growth, which may increase the risk for PH and lung hypoplasia. Impaired lung vascular growth
may increase the risk for environmental stimuli, such as haemodynamic stress, especially with associated
CHD, intermittent or sustained hypoxia with obstructive apnoea or lung disease, viral infection, aspiration
and other factors, to induce more accelerated PH in subjects with Down syndrome than others. Thus, the
genetic consequences of Down syndrome may be linked with disruption of lung vascular and alveolar
growth, suggesting that Down syndrome represents a “developmental lung disease”. The current WSPH
Paediatric Task Force agreed that the phenotype of Down syndrome-related PH is variable and does not
universally fit into a single classification group, but that children with Down syndrome will be classified as
group 3 in the absence of CHD (group 1 or 2).
Diagnosis of paediatric PH
Since the aetiology of PH is very diverse, a methodical and comprehensive diagnostic approach is crucial
to reach an accurate diagnosis and treatment plan. Moreover, IPAH is a diagnosis “per exclusion” and can
be made only by excluding known causes of PH. Despite this, recent registries have shown that most
children do not undergo a complete evaluation [48]. An updated comprehensive paediatric diagnostic
algorithm is shown in figure 1. Special situations may predispose to the development of PAH and should
be considered.
Right heart catheterisation
The Paediatric Task Force addressed several questions regarding the risks and benefits of right heart
catheterisation (RHC) in confirming the diagnosis of PH or PAH in children, and which children may be at
highest risk for adverse events during RHC.
RHC remains the gold standard for the definitive diagnosis and nature of PAH, performing AVT, and
providing useful data for risk stratification. This necessity should be balanced with associated risks. Major
complications associated with RHC in children with PH have been reported to be 1–3%, and are generally
associated with clinical condition and young age (newborns and young infants) [49–52]. As a result,
cardiac catheterisation in paediatric PAH is strongly recommended to be performed in experienced
paediatric PH centres using strategies to prevent these potential complications and having the ability to
manage complications including PH crisis with aggressive interventions such as extracorporeal life support
(ECLS). In rare instances, a child may be too sick to undergo cardiac catheterisation safely (e.g. World
Health Organization Functional Class (WHO FC) IV). In these cases, when the suspicion of PAH is high
and the non-invasive imaging is highly supportive, one should stabilise first and cautiously initiate
appropriate PH therapy under careful observation, most often in the intensive care unit setting. RHC can
then be performed more safely when the patient is sufficiently stabilised. Every attempt should be made
for children with IPAH/HPAH to undergo RHC and AVT safely so one can determine whether they are
acutely responsive to vasoreactivity testing and could benefit from CCB treatment. For those robustly
responsive, but with poor cardiac function, a CCB would not be utilised unless the function improved.
Indications for repeat cardiac catheterisation in children with PH are not well defined, but include
assessment of treatment effect, clinical deterioration, detection of early disease progression, listing for lung
transplantation and prediction of prognosis. It has, however, not been shown whether changes in
haemodynamic parameters are associated with change in clinical outcome and therefore these parameters do
not meet the requirements to serve as established treatment goals.
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Treatment strategies and clinical end-points
Currently, a goal-oriented treatment strategy is suggested for the treatment of paediatric PAH. Despite the
absence of validated treatment goals in paediatric PAH, various treatment guidelines were proposed for
children with PAH, predominantly based on expert opinion [53–56]. An apparent lack of consensus in
these opinions resulted in important differences in reported paediatric treatment recommendations,
stressing the need for evidence.
In 2013, the Paediatric Task Force of the 5th WSPH summarised determinants of higher risk in children,
which included clinical evidence of right ventricular failure, progression of symptoms, syncope, failure to
thrive, WHO FC III or IV, significantly elevated or rising brain natriuretic peptide (BNP) levels,
echocardiographic signs of severe right ventricular enlargement or dysfunction, pericardial effusion, and
haemodynamic parameters such as mPAP/mean systemic arterial pressure (mSAP) ratio >0.75, mean right
atrial pressure (mRAP) >10 mmHg and PVRI >20 WU·m2 [54]. A recent systematic review and
meta-analyses concluded that WHO FC, N-terminal pro-BNP (NT-proBNP)/BNP, mRAP, PVRI, cardiac
index and acute vasodilator response are consistently reported as useful prognostic factors for assessing
long-term outcomes in paediatric PAH, and thus could be used for initial risk stratification and as such
incorporated in recommendations and guidelines [57, 58].
However, parameters with prognostic capabilities are not automatically suitable to serve as a treatment
goal. Treatment goals are either clinically meaningful parameters that reflect how a patient feels or
functions and can thus be a target for treatment, or should be surrogates for survival. Surrogates for
Symptoms, clinical signs, genetic syndromes,
personal or family history suggestive of PH
Yes
Yes Yes
Yes
No
No
NoYes
Yes Perform V/Q scan to rule out CTEPH 
Are mismatched defects present?
Echocardiogram, ECG, chest radiograph compatible 
with PH
Consider most common causes of PH in children 
(i.e. CHD, chronic lung disease)
PH unlikely
Review history, signs, risk factors, PFTs including DLCO,
"polysomnography", chest CT
Consider other causes of symptoms
or re-check
CTEPH suspect: CTA and selective PA angiograms with
referral to PEA expert
Cardiac catheterisation at paediatric centre with AVT:
mPAP >20 mmHg, PAWP ≤15 mmHg and PVRI ≥3 WU·m2; 
include full shunt evaluation to rule out CHD
Diagnosis of lung disease conﬁrmed?
No signs of severe PH or RV dysfunction Signs of moderate–severe PH or RV dysfunction
Treat underlying lung disease Refer to paediatric PH expert
Consider other causes
CTD, HIV, CHD, portopulmonary, drugs/toxins, PVOD/PCH
IPAH/FPAH genetic testing 
(counselling)
Additional diagnostic testing:
Serological markers
Laboratory testing
Liver ultrasound
6MWT/CPET
Cardiac MRI 
Genetic testing?
No
FIGURE 1 Diagnostic algorithm for pulmonary hypertension (PH) in children. CHD: congenital heart disease; PFT: pulmonary function test; DLCO:
diffusing capacity of the lung for carbon monoxide; CT: computed tomography; RV: right ventricular; V/Q: ventilation/perfusion; CTEPH: chronic
thromboembolic PH; CTA: CT angiography; PA: pulmonary artery; PEA: pulmonary endarterectomy; AVT: acute vasodilator testing; mPAP: mean
pulmonary arterial pressure; PAWP: pulmonary arterial wedge pressure; PVRI: pulmonary vascular resistance index; WU: Wood Units; 6MWT:
6-min walk test; CPET: cardiopulmonary exercise test; MRI: magnetic resonance imaging; CTD: connective tissue disease; PVOD: pulmonary
veno-occlusive disease; PCH: pulmonary capillary haemangiomatosis; IPAH/FPAH: idiopathic/familial pulmonary arterial hypertension.
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survival by definition are parameters with a strong correlation with survival, which can be changed by
treatment, while such change should indicate disease worsening or improvement and should be predictive
of long-term outcome.
WHO FC, used in children with PAH and indicating how the child feels and function, has been
demonstrated to be also a strong predictor of transplant-free survival. Moreover, WHO FC has been
shown recently in paediatric PAH to be also a surrogate for survival and as such WHO FC qualifies as a
treatment goal, despite its disadvantage of being a potentially subjective assessment [53]. A functional class
designed specifically for children was proposed in 2011, but is still being considered because of its
complexity and influence by comorbidities, and therefore has not yet reached broad use [59, 60].
In adults with PAH the 6-min walk test (6MWT) has been used to demonstrate drug efficacy. Although
its ability to serve as a surrogate end-point for late outcomes is debatable, the 6MWT may be useful as a
treatment goal in paediatric patients developmentally able to perform the test (children >6 years of age) [61,
62]. Unfortunately, younger children cannot reliably perform the test, making this a suboptimal primary
end-point in a study of the full age range of children. Cardiopulmonary exercise testing (CPET) is even
more demanding with respect to developmental skills and paediatric reference values for CPET in
association with outcome are lacking [63].
Echocardiography seems an obvious tool to monitor treatment effect in children with PH. It provides
functional and structural assessment of the heart and estimates of pulmonary haemodynamics, and is
widely available, non-invasive and well tolerated by children. Unfortunately, echocardiography is also
subject to significant operator and interpretation variability [64]. Where several echocardiographic variables
have been suggested as predictors of outcome in paediatric PAH, today only tricuspid annular plane systolic
excursion (TAPSE) has been shown as strongly associated with improved survival during treatment,
indicating its potential utility as a treatment goal [53]. New echocardiographic modalities for evaluating
right ventricular function (three-dimensional echocardiography, strain and strain rate, and right
ventricular stroke work) as well as magnetic resonance imaging (MRI) assessment of right ventricular
volume and function both hold promise here, but more data in the paediatric population are needed to
determine the value of these techniques regarding establishment of predictive value or surrogacy for
clinical outcomes [65, 66].
In addition to right ventricular function, right ventricular pulmonary vascular coupling reflects right
ventricular afterload, and is regarded to be an important measure for the cardiovascular state and thus
prognosis in patients with PH. MRI and echocardiography are potential candidates for non-invasive
monitoring of this coupling state.
At the pulmonary arterial side of ventricular–arterial coupling, pulmonary arterial stiffness parameters are
gaining interest as prognostic indicators in PAH. Recently, pulmonary vascular stiffness indices have been
shown to predict the development of advanced PAH and mortality in paediatric PVD [67–71].
Serum biomarkers have the advantage of being relatively easy to obtain in peripheral blood and several
biomarkers have been studied in paediatric PAH. Two serum biomarkers have been repeatedly shown to
have prognostic capabilities in paediatric PAH: NT-proBNP and uric acid. A recent meta-analysis
confirmed that NT-proBNP correlated strongly and consistently with survival in children with PAH, and
thus can be used for risk stratification in this population. However, to be used as a treatment target or
clinical end-point, biomarkers should be representative of the disease process and its evolution, which is
often difficult to demonstrate. Nevertheless, changes in NT-proBNP levels following treatment initiation
were recently shown to be predictive for survival in paediatric PAH, indicating that NT-proBNP qualifies
as a treatment goal [72, 73]. Baseline uric acid levels had previously been shown to correlate with survival
in paediatric PAH [74]. More recently, it was shown that the development of uric acid levels over time
correlates with outcome in paediatric PAH [75]. These findings show that uric acid is capable of
predicting outcome not only at baseline, but also during the disease course of PAH, and therefore may
also qualify to be a treatment goal.
Recently, clinical worsening has been introduced as a composite end-point for large randomised controlled
trials (RCTs) in adults with PAH. Components of clinical worsening included unambiguous events such as
death or lung transplantation, which are combined with softer events, including hospitalisations, need for
additional therapy and worsening of function. The use of clinical worsening as an end-point has been
validated in adults with PAH and the soft clinical worsening end-point components were shown to be
highly predictive for subsequent mortality. These results have now been reproduced in the paediatric PAH
population using clinical worsening components: death, lung transplantation, non-elective PAH-related
hospitalisations, including hospitalisations for atrial septostomies, initiation of i.v. prostanoids and
functional deterioration (worsening of WHO FC, ⩾15% decrease in 6MWD or both) [76]. Moreover, this
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study showed that clinical worsening occurred with a high event rate in paediatric PAH, indicating that
clinical worsening may serve as a suitable end-point in future paediatric trials.
Monitoring daily physical activity has also been suggested as an alternative tool to assess functional
capacity in children. A recent pilot study using three-axis accelerometry in 29 children with PAH and 60
controls showed that physical activity was markedly decreased in children with PAH, and that
accelerometer output correlated with clinical disease severity markers and predicted outcome [77]. Larger
studies are in progress to validate the use of accelerometry output as a clinically meaningful end-point for
clinical trials in paediatric PAH.
In summary, the emerging paediatric data provide increasing evidence and support for the risk
stratification model proposed by the WSPH Paediatric Task Force in 2013, with some minor modifications
in 2018. For example, the prognostic significance of syncope could not be demonstrated and is therefore
questioned as a high-risk factor for poor outcomes. Importantly, upcoming evidence suggests that in
paediatric PAH striving for a low-risk profile using this WSPH paediatric risk assessment tool might also
be used as treatment target, as has recently been suggested in adults [78–80].
Updates to the paediatric treatment algorithm
The prognosis of children with PAH has improved in the past decade owing to new therapeutic agents
and aggressive treatment strategies. However, the use of targeted pulmonary PAH therapies in children is
almost exclusively based on experience and data from adult studies, rather than evidence from clinical
trials in paediatric patients. Due to the complex aetiology and relative lack of data in children with PAH,
selection of appropriate therapies remains difficult. We propose a pragmatic treatment algorithm based on
the strength of expert opinion that is most applicable to children with IPAH (figure 2). The ultimate goal
of treatment should be improved survival and to facilitate normal activities of childhood without
self-limitation.
Background therapy with diuretics, oxygen, anticoagulation and digoxin should be considered on an
individual basis. Care should be taken to not overly decrease intravascular volume due to the pre-load
dependence of the right ventricle. Following the complete evaluation for all causes of PH, AVT is
recommended to help determine therapy.
In children with a positive AVT response, oral CCBs may be initiated [2–4]. In the child with a sustained
and improved response, CCBs may be continued, but patients may deteriorate, requiring repeat evaluation
and additional therapy [81]. Clinical experience suggests that these children remain on CCBs in addition
to targeted PAH therapy. For children with a negative AVT response or in the child with a failed or
Positive
No
Yes
Negative
Expert referral
General: consider diuretics,
oxygen, anticoagulation, digoxin Acute vasoreactivity testing
ERA or PDE5i (oral)
Oral/inhaled prostacyclin/prostacyclin agonist
Consider combination therapy
(sequential or upfront)
Lower risk
Serial reassessment#
Epoprostenol or
treprostinil (i.v./s.c.)
Consider early combination
Higher risk
Atrial
septostomy
Lung 
transplant
Oral CCB
Continue
CCB
Improved and
sustained
reactivity
Potts shunt
FIGURE 2 Paediatric idiopathic/familial pulmonary arterial hypertension treatment algorithm. CCB: calcium channel blocker; ERA: endothelin
receptor agonist; PDE5i: phosphodiesterase type 5 inhibitor. #: deterioration or not meeting treatment goals.
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non-sustained response to CCBs, risk stratification should determine additional therapy (table 6).
Although the specific number of lower- or higher-risk criteria to drive therapeutic choices is not yet
known, a greater proportion of either should be considered as justification for therapy. As in adult
patients, determinants of higher risk in children include clinical evidence of right ventricular failure,
progression of symptoms, WHO FC III or IV, significantly elevated or rising BNP/NT-proBNP levels,
severe right ventricular enlargement or dysfunction and pericardial effusion. Additional haemodynamic
parameters that predict higher risk include mPAP/mSAP ratio >0.75 [82], mRAP >10 mmHg and PVRI
>20 WU·m2 [83]. Additional high-risk parameters include failure to thrive. In the child with a negative
acute vasoreactivity response and lower risk, initiation of oral monotherapy is recommended. Treatment of
choice is an endothelin receptor antagonist (bosentan [83–90], ambrisentan [91, 92]) or phosphodiesterase
type 5 (PDE5) inhibitor (sildenafil [93–100], tadalafil [101, 102]).
Children who deteriorate on either endothelin receptor antagonists or PDE5 inhibitors may benefit from
consideration of early combination therapy (add-on or up-front). If the child remains in a low-risk
category, addition of inhaled prostacyclin (iloprost [103–106], treprostinil [107]) to background therapy
may be beneficial. It is crucial to emphasise the importance of continuous repeat evaluation for
progression of disease in children on any of these therapies. In children who are at higher risk, initiation
of i.v. epoprostenol [108, 109] or treprostinil [110] should be strongly considered. Experience using s.c.
treprostinil in children is increasing as well [111–113]. In the child deteriorating with high-risk features,
early consideration of lung transplantation and interventional palliative bridges are important.
Interventional palliative bridges
Atrial septostomy
Atrial septostomy in children with IPAH has been performed to treat syncope, and improve cardiac
output and systemic oxygen carrying capacity, especially in countries without easy access to targeted PH
drugs or in IPAH refractory to medical therapy, or as a bridge to lung transplantation [114]. Atrial
septostomy improves symptoms and quality of life in paediatric PAH, and may serve as a bridge to lung
transplantation [56]. It appears to be safe in centres with experience, and one study reported lung
transplantation-free and repeat-balloon atrial septostomy (BAS)-free survival at 30 days, 1 year and 5 years
was 87%, 61% and 32%, respectively [115].
However, in most cases BNP levels do not change after BAS and it seems likely that the creation of the
Potts shunt (see following subsection) may ultimately be the preferred procedure as in contrast to BAS it
unloads the pulmonary vascular bed, as well as the right ventricle with preserved oxygenation to the upper
TABLE 6 Determinants of paediatric idiopathic/heritable pulmonary arterial hypertension risk
Lower risk Determinants of risk Higher risk
No Clinical evidence of RV failure Yes
No Progression of symptoms Yes
>350 6MWT (>6 years old) m <350
Normal Growth Failure to thrive
I, II WHO FC III, IV
Minimally elevated Serum BNP/NT-proBNP Significantly elevated
Rising level
Echocardiography RA/RV enlargement
Reduced LV size
Increased RV/LV ratio
Reduced TAPSE
Low RV FAC
Pericardial effusion
Systemic CI >3.0 L·min−1·m−2 Haemodynamics Systemic CI <2.5 L·min−1·m−2
Systemic venous saturation >65% mRAP >10 mmHg
Acute vasoreactivity PVRI >20 WU·m2
Systemic venous saturation <60%
PACI <0.85 mL·mmHg−1·m−2
RV: right ventricle; 6MWT: 6-min walk test; WHO: World Health Organization; FC: Functional Class; BNP:
brain natriuretic peptide; NT-proBNP: N-terminal pro-BNP; RA: right atrium; LV: left ventricle; FAC:
fractional area change; TAPSE: tricuspid annular plane systolic excursion; CI: cardiac index; mRAP: mean
right atrial pressure; PVRI: pulmonary vascular resistance index; WU: Wood Units; PACI: pulmonary
arterial compliance index.
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body including coronary and cerebral vessels. Relative contraindications for atrial septostomy include
1) mRAP >20 mmHg, 2) resting arterial oxygen saturation <90%, 3) severe right ventricular failure and
4) patients with impending death.
Atrial septostomy may be considered in the child with worsening PAH despite optimal medical therapy,
but should be considered before the later stages with increased risk. Atrial septostomy can be considered
in patients with WHO FC III and IV symptoms and recurrent syncope on combined medical therapy, as
palliative bridge to transplant, increasing the chance for survival while waiting for a donor organ.
Reversed Potts shunt
The Paediatric Task Force also discussed whether the reversed Potts shunt should be offered to children with
severe IPAH/HPAH who are refractory to medical therapy.
Surgical creation of a palliative reversed Potts shunt (left pulmonary artery to descending aorta) has been
described as a new option for severely ill children with suprasystemic IPAH [56, 116]. This surgical
procedure implies the creation of a connection between the left pulmonary artery and the descending
aorta, which allows right-to-left shunting, similar to a patient with patent ductus arteriosus-related
Eisenmenger syndrome. The use of a reversed Potts shunt in suprasystemic PH is considered advantageous
compared with atrial septostomy as it provides high oxygen saturated blood to the coronary arteries and
the central nervous system, and only causes desaturation of the lower body. Another benefit arises from its
effect on haemodynamics by the relief of right ventricular pressure overload in systole and, in part, also in
diastole, with a subsequent reduction in shifting of the interventricular septum towards the left ventricle
with an improvement in systolic and diastolic left ventricular performance. A run-off through the Potts
shunt, if too big, with decreased pulmonary perfusion and extreme desaturation of the lower body, with
subsequent undersupply of the myocardium and the brain, should be avoided. The procedure may be
considered in patients with suprasystemic PH refractory to any medical treatment, including combined
therapy presenting with WHO FC IV symptoms.
The largest series published consisted of 24 children with drug-refractory PAH in which a permanent
Potts shunt was created (19 surgical left pulmonary artery–descending aorta, six via stenting of a persistent
ductus arteriosus) [117]. Six patients experienced severe post-operative complications and there were three
early deaths related to low cardiac output. After a median follow-up of 2.1 years, the 21 survivors showed
persistent improvement in functional capacities and none of the patients had syncope or overt right
ventricular failure [76]. These favourable long-term results suggest that creation of a Potts shunt can be a
valuable alternative, or bridge to bilateral lung transplantation, at least in selected cases.
Recently, several case series demonstrated the feasibility of the pure catheter-based interventional
implementation of the connection between the left pulmonary artery and the descending aorta [118]. The
most elegant method is obviously the implantation of a stent in a still patent persistent ductus arteriosus,
which is not infrequently present in infants and young children. This procedure is an established method
in CHD with duct-dependent circulation and can be established with considerable low peri-procedural risk
in experienced centres. The interventional de novo creation of a left pulmonary artery–descending aorta
connection with a covered stent from the left pulmonary artery or descending aorta side [119] has been
shown to be feasible, but currently must be considered a high-risk procedure in patients with end-stage
PAH who are too sick to undergo surgery and only in a programme with expertise in performing this
procedure. SALNA et al. [120] described a novel successful approach to the Potts shunt in a young adult
with IPAH using a unidirectional valved shunt from the main pulmonary artery to the descending aorta,
which has the advantage of preventing any back flow from the aorta when the PAP is subsystemic and
during diastole. Whether this will prove to be a preferred approach remains to be seen. The current
WSPH Paediatric Task Force decided to include the Potts shunt in the treatment algorithm, but cautions
that it should only be done in selected patients in a centre with the expertise to perform the procedure,
including ECLS back-up (figure 2). Whether this is preferred over an atrial septostomy will require further
experience and study.
Clinical trial design
The Paediatric Task Force further discussed whether we can develop new paediatric-specific clinical
end-points in clinical trial design.
Our understanding of the pathobiology and treatment of children with PH has improved considerably
during the past 20 years, but treatment is still based on clinical trial evidence of efficacy from clinical trial
data in adults, individual clinical experience, registry data, short-term trials and open-label studies. RCTs
have not been conducted. Clinical trials in adults are most helpful when conducted on the most
homogeneous, “purest” form of the disease, i.e. IPAH, but this is rare in children. Growth and
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development entail constant hormonal and metabolic change necessitating age-related study,
understanding the effect on long-term outcome is crucial and choice of end-points is difficult [121]. The
European Medicines Agency (EMA) and US FDA both require RCTs, but the EMA emphasises the need
for pharmacokinetic and safety studies, which have been done in some instances, while the US FDA seeks
to include a clinical end-point for evidence of efficacy. Relevant clinical end-points include death,
transplantation and hospitalisation, and determining how the child feels. The traditional means of
evaluation in adults, such as the 6MWT, are obviously not applicable to young children. Potential
surrogate end-points in children include weight, echocardiography, biomarkers (primarily NT-proBNP),
MRI and exercise testing. None of these possibilities have been fully validated. Haemodynamic evaluation
does not seem to be an appropriate end-point since there are ethical considerations and sequential studies
are not known to relate to long-term outcome. Recruitment, retention and evaluation of a continually
maturing small population of children is a considerable challenge.
However, since the 5th WSPH, paediatric-specific biomarkers, such as functional classification, TAPSE and
NT-proBNP, growth and composite clinical end-points have been evaluated. TAPSE, NT-proBNP and
WHO FC identified transplant-free survival in 70 children with PAH [53]. Height for weight was also
identified as a clinical end-point [122]. The Panama “Paediatric Functional Class” correlated well with
outcome [60]. A composite end-point of clinical worsening composed of death, lung transplantation and
initiation of parenteral prostanoid therapy was identified [53, 76]. A novel approach to clinical evaluation
of treatment efficacy or disease progression may be the use of home accelerometers and a pilot study
suggested that there is a difference in spontaneous physical activity in children with PAH compared with
controls [77]. Thus, paediatric-specific clinical end-points and trial design are evolving.
Conclusions
Despite many unique characteristics, children with PH are often assessed and managed based on adult PH
guidelines. This current WSPH Paediatric Task Force had an opportunity to further highlight some of the
inherent differences between children and adults with PH, novel findings in paediatric PH since the 5th
WSPH meeting in 2013, and develop additional current paediatric-specific recommendations. The current
2018 6th WSPH classification incorporates the growing population of children with developmental lung
diseases, such as BPD and CDH, complex CHD, and novel mutations. The Paediatric Task Force
addressed a new definition for PAH and AVT in children, a novel palliative bridge approach with the
reversed Potts shunt, and clinical trial design. The field of paediatric PH still requires future
paediatric-specific clinical trials in order to develop specific treatment strategies and clinical end-points for
children with PH.
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